Description: Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Home Page: www.graybug.vision
GRAY Technical Analysis
203 Redwood Shores Parkway
Redwood City,
CA
94065
United States
Phone:
650 487 2800
Officers
| Name | Title |
|---|---|
| Dr. Frederic Guerard Pharm.D. | Pres, CEO, Sec. & Director |
| Mr. Robert S. Breuil | CFO & Treasurer |
| Dr. Gerald D. Cagle Ph.D. | Sr. Advisor & Head of Bus. Devel. |
| Dr. Parisa Zamiri M.D., Ph.D. | Chief Medical Officer |
| Dr. Peter A. Campochiaro M.D. | Co-Founder |
| Dr. Peter J. McDonnell M.D. | Co-Founder |
| Ms. Bettina Maunz | Chief People Officer & Head of Communications |
| Mr. Ming Yang | Sr. VP of R&D |
| Dr. Ward M. Peterson Ph.D. | Sr. VP of Preclinical Devel. |
| Mr. Ali Kakavand Ph.D. | VP & Head of Program Management |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2956 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |